Recruiting Multiple Myeloma Studies in Austin
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab...
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
The purpose of the phase 1 part of this study is to evaluate how well pirtobrutinib is tolerated and what side effects may occur. The phase 2 part of the study will further investigate efficacy and sa...
About Multiple Myeloma Clinical Trials in Austin
Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.
There are currently 2 multiple myeloma clinical trials recruiting participants in Austin, TEXAS. These studies are seeking a combined 138 participants. Research is being sponsored by Pfizer, Eli Lilly and Company. Clinical trial participation is free and participants receive study-related medical care at no cost.
Multiple Myeloma Clinical Trials in Austin — FAQ
Are there multiple myeloma clinical trials in Austin?
Yes, there are 2 multiple myeloma clinical trials currently recruiting in Austin, TEXAS. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Austin?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Austin research site will contact you about next steps.
Are clinical trials in Austin free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Austin studies also compensate for your time and travel.
What multiple myeloma treatments are being tested?
The 2 active trials in Austin are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.
Data updated March 2, 2026 from ClinicalTrials.gov